Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Autogel in Progressive Neuroendocrine Tumours
NCT00326469Phase 2Completed
- Sponsor
- Ipsen
- Start
- May 2006
- Primary completion
- Nov 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lanreotide in neuroendocrine tumors (NETs), sponsored by Ipsen. Primary endpoint: Time to disease progression at Month 24. Started May 2006; status: completed.
02
Drugs
lanreotide
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT00326469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00326469.